We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...

Doctors have begun noticing a trend among their colleagues: many have visibly shed pounds, and it's all thanks to drugs like ...